We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.63B
AUM Growth
+$871M
Cap. Flow
-$403M
Cap. Flow %
-7.15%
Top 10 Hldgs %
32.98%
Holding
166
New
29
Increased
30
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$235M
2
AHCO icon
AdaptHealth
AHCO
+$145M
3
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$132M
4
ORGO icon
Organogenesis Holdings
ORGO
+$78.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50.1M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$110M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$88.6M
3
BIIB icon
Biogen
BIIB
+$86.7M
4
CNC icon
Centene
CNC
+$67.9M
5
TOI icon
The Oncology Institute
TOI
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 68.23%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
26
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$45.3M 0.8%
+657,005
New +$50.1M
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.32B
$44.8M 0.8%
2,835,000
+229,620
+9% +$3.12M
HOWL icon
28
Werewolf Therapeutics
HOWL
$17.9M
$44.5M 0.79%
+2,552,787
New +$35M
APR
29
DELISTED
Apria, Inc. Common Stock
APR
$44M 0.78%
1,572,892
+372,892
+31% +$11M
ONCR
30
DELISTED
Oncorus, Inc.
ONCR
$43.5M 0.77%
3,148,977
– –
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$42.5M 0.75%
300,000
-120,000
-29% -$13.6M
ACH
32
Accendra Health
ACH
$254M
$42.2M 0.75%
996,500
-552,500
-36% -$21.5M
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$7.17B
$39M 0.69%
1,989,625
– –
KURA icon
34
Kura Oncology
KURA
$948M
$37.4M 0.66%
+1,794,000
New +$44.5M
INZY
35
DELISTED
Inozyme Pharma
INZY
$37.1M 0.66%
2,178,985
+214,985
+11% +$3.74M
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$36.4M 0.65%
5,767,409
– –
PBYI icon
37
Puma Biotechnology
PBYI
$422M
$34.6M 0.61%
3,769,795
– –
BDSI
38
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$34.1M 0.61%
9,530,000
– –
NUVB icon
39
Nuvation Bio
NUVB
$2.18B
$33.3M 0.59%
3,577,233
+577,233
+19% +$6.58M
WVE icon
40
Wave Life Sciences
WVE
$1.1B
$32.2M 0.57%
4,829,069
+1,326,099
+38% +$8.66M
VIVO
41
DELISTED
Meridian Bioscience Inc
VIVO
$31.6M 0.56%
1,424,274
+535,005
+60% +$11.3M
ORTX
42
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$30.5M 0.54%
694,942
– –
ARDX icon
43
Ardelyx
ARDX
$1.26B
$28.9M 0.51%
3,811,554
+1,250,000
+49% +$9.24M
TERN
44
DELISTED
Terns Pharmaceuticals
TERN
$28.8M 0.51%
2,345,959
– –
CALC icon
45
CalciMedica
CALC
$11.1M
$28.7M 0.51%
377,265
– –
FOLD
46
DELISTED
Amicus Therapeutics
FOLD
$28.4M 0.5%
2,941,492
+242,995
+9% +$2.37M
ITMR
47
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$28.1M 0.5%
1,193,803
– –
LENZ
48
LENZ Therapeutics
LENZ
$156M
$27.9M 0.49%
+129,473
New +$22.6M
XLRN
49
DELISTED
Acceleron Pharma
XLRN
$27.5M 0.49%
219,500
– –
PMVP icon
50
PMV Pharmaceuticals
PMVP
$68.3M
$27.5M 0.49%
804,000
+380,320
+90% +$12.7M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2021 Portfolio in Review

As of Q2 2021, Deerfield Management held 166 positions worth $5.63B, up 18% from $4.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $403M in Q2 2021, closing 23 positions and reducing 12 holdings. Its most notable exit was Boston Scientific, an estimated $110M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Singular Genomics Systems, Inc. Common Stock worth $250M.

  • Deerfield Management's largest Q2 2021 buy was Singular Genomics Systems, Inc. Common Stock: 303,734 shares worth $250M.
  • Deerfield Management added most to AdaptHealth in Q2 2021, an estimated $145M increase.
  • Deerfield Management's biggest Q2 2021 reduction was Centene, cutting an estimated $67.9M.
  • Deerfield Management fully exited Boston Scientific in Q2 2021, selling an estimated $110M.
  • Deerfield Management's ten largest holdings make up 33% of its $5.63B portfolio in Q2 2021.
  • Deerfield Management opened 29 new positions and closed 23 in Q2 2021.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $5.63B.

Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.